United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - mometasone furoate - cutaneous cream - 1mg/1gram

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc.,usa - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine maleate capsules are indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with trimipramine maleate or within 14 days of stopping treatment with trimipramine maleate is contraindicated because of an increased risk of serotonin syndrome. the use of trimipramine maleate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting trimipramine maleate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also co

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glenmark pharmaceuticals (europe) ltd. - atovaquone 250 mg; proguanil hydrochloride 100 mg - film-coated tablet - 250 mg - 100 mg - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 60,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 90,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 120,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - inhaler - see ingredients - each actuation delivers salbutamol sulphate 100,0 ug

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - #n/a - not indicated - none